FTC Claims Martin Shkreli Violated Lifetime Pharma Ban in Live Stream

The Federal Trade Commission disclosed on Wednesday that former biotech mogul Martin Shkreli aired a live video that appears to breach the permanent prohibition preventing him from working in the pharmaceutical field. The agency noted the footage, posted on a public streaming site, captured Shkreli handling drug‑related documents and talking about prospective business arrangements, actions that directly violate his settlement terms.

Shkreli first captured national attention in 2015 when his firm, Turing Pharmaceuticals, hiked the price of Daraprim—a drug used to treat a parasitic infection—by more than 4,000 percent. The steep increase provoked widespread fury and sparked a criminal probe that later uncovered a separate securities‑fraud scheme. In 2018, a federal jury found him guilty of securities fraud, resulting in a seven‑year prison sentence.

Alongside the criminal punishment, a civil accord with the FTC instituted a lifelong ban on Shkreli’s participation in any capacity within the pharmaceutical industry. The order bars him from manufacturing, marketing, or even advising on drug products and obliges him to abstain from any activity that could sway the prescription‑medicine market.

Per the FTC’s release, the livestream—recorded in early August—showed Shkreli seated at a desk amid medical‑industry literature. He spoke candidly about “getting back into the game” and mentioned contacts at a venture‑capital firm that backs biotech startups. The clip was uploaded to a well‑known live‑streaming platform and stayed online for several hours before being taken down after a takedown request.

In reply, the commission said it is weighing a suite of enforcement measures, including further monetary fines and possibly asking a court to impose tighter supervisory conditions. The FTC stressed that breaches of lifelong bans are uncommon but are treated seriously, as they erode the agency’s capacity to shield consumers from fraud and abusive conduct.

The episode revives discussion about how effectively regulators can monitor high‑profile figures who operate chiefly online. Consumer advocates contend the Shkreli case underscores a need for stronger digital surveillance tools, while civil‑liberties groups warn against overreach. Whatever the result, the FTC’s forthcoming actions are likely to set a benchmark for dealing with comparable violations in an ever‑more connected marketplace.